Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma

Abstract

This study examined the promoter methylation of APO-1/CD95 (Fas) gene in bladder urothelial carcinoma and analyzed the relationship between the Fas promoter methylation and the biological behavior of bladder cancer. Promoter methylation of Fas gene was detected by methylation-specific PCR (MSP) in 4 bladder cancer cell lines, 50 human bladder urothelial carcinoma samples and l0 normal bladder tissue samples. Correlation of the aberrant methylation of Fas promoter with the clinicopathological parameters was statistically analyzed. The results showed that Fas was down-regulated at both mRNA and protein level in bladder cancer cell lines and tissue samples of bladder urothelial carcinoma. The positive rate of Fas protein expression in bladder urothelial carcinoma was 34.0% (17/50), significantly lower than that in normal bladder tissues (70.0%, 7/10) (P<0.01). Fas promoter methylation was detected, and the positive rate of Fas promoter methylation in bladder urothelial carcinoma was 42.0% (21/50), which was obviously higher than that in normal bladder tissues (0.0%, 0/10) (P<0.01). The aberrant methylation of Fas promoter was reversely correlated with Fas protein expression (P<0.05). Furthermore, the positive rates of Fas promoter methylation in high-grade and low-grade bladder urothelial carcinoma were 73.3% (11/15) and 34.2% (12/35), respectively, with significant difference shown (P<0.05). No statistical significance was found in the Fas promoter methylation among different clinical stages of bladder cancer. It was concluded that Fas promoter hypermethylation plays an important role in the pathogenesis of bladder urothelial carcinoma and may serve as a prognostic indicator of bladder urothelial carcinoma.

Keywords

bladder / carcinoma / Fas / methylation

References

[1] HuZ.B.. The expression and significance of Fas in human body. Sect Immunol Foreig Med Sci (Chinese), 2000, 23(1): 8-11

[2] ChinnaiyanA.M., O’RourkeK., TewariM., et al.. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 1995, 81(4): 505-512

[3] BoldinM.P., MettI.L., VarfolomeevE.E., et al.. Self-association of the “death domains” of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem, 1995, 270(1): 387-391

[4] LuoB.. The expression of VEGF and E-cadherin in bladder transitional carcinoma tissue. Acta Academiae Medicinae Qingdao Universitatis (Chinese), 2005, 41(4): 317-319

[5] ChinnaiyanA.M., O’RourkeK., YuG.L., et al.. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science, 1996, 274(5289): 990-992

[6] TrauzoldA., SchmiedelS., RöderC., et al.. Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer, 2003, 89(9): 1714-1721

[7] TourneurL., MistouS., MichielsF.M., et al.. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene, 2003, 22(18): 2795-2804

[8] MishimaK., NariaiY., YoshimuraY.. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int J Cancer, 2003, 105(5): 593-600

[9] JeltschA.. Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem, 2002, 3(4): 274-293

[10] EstellerM.. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol, 2005, 17(1): 55-60

[11] EstellerM., CornP.G., BaylinS.B., et al.. A gene hypermethylation profile of human cancer. Cancer Res, 2001, 61(8): 3225-3229

[12] NatarajanA.T., VermeulenS., DarroudiF., et al.. Chromosomal localization of human O⁶-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis, 1992, 7(1): 83-85

[13] EstellerM., RisquesR.A., ToyotaM., et al.. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res, 2001, 61(12): 4689-4692

[14] EstellerM., ToyotaM., Sanchez-CespedesM., et al.. Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res, 2000, 60(9): 2368-2371

[15] SrivenugopalK.S., Ali-OsmanF.. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a prote olytic target for the E6 human papillomavirus oncoprotein. Oncogene, 2002, 21(38): 5940-5945

[16] ZhengC.Q., JiS.P., GongF., et al.. Detection of hypermethylated MGMT, hMLH1 and hMSH2 genes in tumor and serum DNA of gliomas patients. J Med Mol Biol (Chinese), 2009, 6(1): 1-5